<DOC>
	<DOCNO>NCT00358371</DOCNO>
	<brief_summary>Primary objective : To study absolute bioavailability , distribution elimination parameter flucloxacillin two oral formulation flucloxacillin healthy male and/or female subject .</brief_summary>
	<brief_title>Bioavailability Of Flucloxacillin Capsules ( 250 mg 500 mg )</brief_title>
	<detailed_description>A mono-center , open , randomize , three-way , twelve-sequence , cross-over study determine extent absorption ( absolute bioavailability ) , rate absorption characterize distribution elimination characteristic commercial 250 mg 500 mg capsule flucloxacillin give single oral dose vs. one 250 500 mg intravenous dose 24 healthy male and/or female subject fast state</detailed_description>
	<mesh_term>Floxacillin</mesh_term>
	<criteria>Healthy volunteer , Caucasians , Body Mass Index ( BMI ) 19 27 kg/m 2 ; physically mentally healthy judged mean medical standard lab examination ; nonsmoker , exsmokers moderate smoker . Exclusion criterion : medical history , vital sign , physical examination , laboratory test ( blood and/or urine ) evidence clinically significant condition ; 12lead electrocardiogram ( ECG ) clinically significant abnormality ; acute infection within 2 week precede 1st study drug administration ; medication regular basis ( exception female : oral contraceptive ) and/or tricyclic antidepressant , antacid , histamine H2receptor antagonists , antibiotic , non steroid antiinflammatory drug anticoagulant within 8 week 1st study drug administration and/or agreement take drug include Overthecounter ( OTC ) drug end follow examination ; agreement take medication , include OTC medicine , antacid , analgesic within 2 week 1st drug administration end followup examination ; special diet loss &gt; 5 kg within last month weight reduction diet ; regularly consume large quantity alcohol ( &gt; 20g/day ) and/or beverage contain methylxanthines e.g . caffeine ( &gt; 0.5L/day altogether ) ; agreement consume : beverage food contain alcohol 48 h prior 1st study drug administration end followup examination ; grapefruit product 7 day prior 1st study drug administration end followup examination , beverages food contain methylxanthines well fruitjuices food contain poppy seed 48 h 1st drug administration either study period last blood sample respective study period collect , consume chew confinement ; history : allergy flucloxacillin , Blactams and/or relate drug , know hypersensitivity inactive ingredient study medication , hypersensitivity multiple drug , allergic disease , acute hay fever , previous history flucloxacillinassociated jaundice/hepatic dysfunction , alcohol drug abuse , epilepsy seizure , psychiatric illness , e.g . latent manifest depression schizophrenia , neurosis , respiratory disease , surgery gastrointestinal tract ( except appendectomy ) , kidney disease , bleeding/coagulation disorder severe anaemia , glucose6phosphate dehydrogenase deficiency and/or chronic treatment chronic pathology ; metabolic disease ; evidence disorder metabolism pharmaceutical foreign compound ; cardiovascular disease e.g . hypertension , hypotension bradycardia ; associate disease would interfere clinical course trial ; major illness 3 month commencement screen period , gastrointestinal disease ; report positive result test drug abuse ( amphetamine , opiate , barbiturate , methadone , cannabinoids , cocaine , benzodiazepine ) ; Positive test : alcohol , HepatitisBantigen HepatitisCantibody , HIVantibody ; blood donor blood loss include plasmapheresis within last 3 month 1st study drug administration ; intake depot injectable solution ( include study medication ) within 6 month 1st study administration ; intake enzymeinducing and/or organotoxic drug within 4 week 1st study drug administration ; female : positive result pregnancy test ; use agree use adequate contraceptive method study ; lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>bioavailability flucloxacillin</keyword>
</DOC>